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Abstract 
Loss of ABCA1 activity in Tangier disease (TD) is associated with abnormal apoB lipoprotein 
(Lp) metabolism in addition to the complete absence of high density lipoprotein (HDL). We used 
hepatocyte-specific ABCA1 knock-out (HSKO) mice to test the hypothesis that hepatic ABCA1 
plays dual roles in regulating Lp metabolism and nascent HDL formation. HSKO mice 
recapitulated the TD lipid phenotype with postprandial hypertriglyceridemia, markedly 
decreased LDL, and near absence of HDL. Triglyceride (TG) secretion was 2-fold higher in 
HSKO compared with wild type mice, primarily due to secretion of larger TG-enriched VLDL 
secondary to reduced hepatic phosphatidylinositol 3-kinase signaling. HSKO mice also displayed 
delayed clearance of postprandial TG and reduced post-heparin plasma lipolytic activity. In 
addition, hepatic LDLr expression and plasma LDL catabolism were increased 2-fold in HSKO 
compared with wild type mice. Last, adenoviral repletion of hepatic ABCA1 in HSKO mice 
normalized plasma VLDL TG and hepatic phosphatidylinositol 3-kinase signaling, with a partial 
recovery of HDL cholesterol levels, providing evidence that hepatic ABCA1 is involved in the 
reciprocal regulation of apoB Lp production and HDL formation. These findings suggest that 
altered apoB Lp metabolism in TD subjects may result from hepatic VLDL TG overproduction 
and increased hepatic LDLr expression and highlight hepatic ABCA1 as an important regulatory 
factor for apoB-containing Lp metabolism. 
Keywords: ABC Transporter, Hepatocyte, Lipoprotein, Low Density Lipoprotein (LDL), PI 3-
Kinase, Very Low Density Lipoprotein (VLDL) 
Introduction 
ABCA1 (ATP-binding cassette transporter A1) is indispensable in the initial steps of high 
density lipoprotein (HDL)2 formation and the process of reverse cholesterol transport from 
peripheral tissues to the liver. ABCA1 is expressed in many cells; however, hepatocytes make 
the single most important contribution to plasma HDL concentration (1,–3). Mutations in ABCA1 
in humans cause Tangier disease (TD), an autosomal recessive disorder characterized by severe 
HDL deficiency, rapid plasma clearance of HDL and apoA-I, sterol deposition in tissues, and 
premature coronary atherosclerosis (4,–7). 
In addition to HDL deficiency, TD subjects have significantly elevated plasma TG and a 50% 
reduction in LDL cholesterol concentrations (4, 8). The TG phenotype in TD disease is 
complicated, with most, but not all, TD subjects displaying elevated fasting or postprandial TG 
elevations (9). Clee et al. (8) reported an inverse relationship between dysfunctional ABCA1 
alleles and plasma TG concentrations. In addition, data from case reports of 59 Tangier patients 
show variable TG concentrations, with mean, median, minimum, and maximum concentrations 
of 210, 175, 40, and 580 mg/dl, respectively (4). The underlying mechanisms for the increased 
plasma TG and decreased LDL concentrations in TD subjects have not been established. In one 
study, apoA-II enrichment of VLDL of TD subjects was proposed to result in reduced reactivity 
of VLDL with lipoprotein lipase (LPL) (9, 10). Another study suggested that ABCA1-dependent 
cholesterol efflux decreases VLDL secretion from murine hepatocytes by limiting cholesterol 
availability for VLDL assembly (11). However, whether deficiency of ABCA1 is associated with 
increased apoB lipoprotein secretion in vivo is unknown. 
Recently, we reported that silencing of ABCA1 in rat hepatoma cells is associated with PI3K-
dependent enhanced secretion of TG-enriched VLDL (12), suggesting a potential role of hepatic 
ABCA1 expression in VLDL assembly and secretion. To determine whether hepatic ABCA1 
expression affects VLDL secretion in vivo, we used loss of function and gain of function 
strategies with hepatocyte-specific gene targeting of ABCA1 and adenoviral overexpression of 
human ABCA1, respectively. We demonstrate that targeted inactivation of hepatic ABCA1 
increases VLDL production and LDL clearance, recapitulating the TD lipid phenotype, and that 
adenoviral rescue of ABCA1 reverses the elevated plasma TG phenotype. These studies 
highlight a novel and important role for hepatic ABCA1 in regulating apoB Lp metabolism. 
EXPERIMENTAL PROCEDURES 
Animals and Diet  
Generation and genotyping of HSKO (albumin Cre+, ABCA1flox/flox), hetero-HSKO (albumin 
Cre+, ABCA1flox/+), and wild type control (albumin Cre+, ABCA1+/+) mice were performed as 
described previously (1). The HSKO mice used for this study were backcrossed into the 
C57BL/6 background and determined to be >99% in that background by genome-wide screens 
using 134 single nucleotide polymorphisms that were polymorphic between the C57BL/6 and 
129/SvEv strains and spaced ∼20 megabase pairs across the mouse genome. HSKO mice were 
also crossed with LDL receptor knock-out (LDLrKO) mice (Jackson Laboratories). The mice 
were housed in the Wake Forest University Health Sciences animal facility with a 12-h light (6 
a.m. to 6 p.m.)/12-h dark cycle and maintained on a chow diet (Prolab RMH3000 rodent diet, 
LabDiet). In most studies, 12–16-week-old male mice were used. In one study, 8-week-old mice 
were fed an HF diet containing 45% calories from fat (90% from lard), 35% calories from 
carbohydrate (50% from sucrose), and 20% from protein for 8 weeks. All protocols and 
procedures were approved by the Wake Forest University Health Sciences Animal Care and Use 
Committee. 
Analysis of Plasma and Liver Lipids  
Plasma was collected by tail bleeding of 6-h fasted or non-fasted mice. To determine lipoprotein 
lipid distribution, pooled plasmas were either fractionated by two Superose 6 FPLC columns (1 × 
30 cm) in series (flow rate 0.5 ml/min; Fig. 1D) (1) or by a high resolution Superose 6TM FPLC 
column (10/300GL, Amersham Biosciences; flow rate 0.5 ml/min; see Fig. 6, D–F). Fractions 
eluting from the columns were used for enzymatic determination of total plasma cholesterol 
(TPC) and TG. In Fig. 5F, TPC distribution in whole plasma was determined using a high 
resolution Superose 6 column (1 × 30 cm) and an online cholesterol analyzer (Elite La Chrome, 
Hitachi). Total cholesterol and triglyceride concentrations were determined by an enzymatic 
colorimetric assay using a commercial kit (Chol and Trig/GB, Roche Applied Science). For the 
free fatty acid composition analysis, lipid extracts from liver were fractionated into cholesteryl 
ester, TG, and phospholipid bands by TLC, and then each fraction was methylated and analyzed 
by gas-liquid chromatography (13). For the quantification of hepatic free fatty acid content, liver 
lipid extracts (Bligh-Dyer extraction) were dried down under N2, solubilized with 1% Triton X-
100 (14), and then quantified using a commercial NEFA assay kit (Wako). 
Liver Perfusion  
Recirculating liver perfusion was carried out as described previously (15). Ten ml of perfusate 
medium with erythrocytes (10% hematocrit) were pumped through livers at 1 ml/min for 3 h. 
Every 30 min during perfusion, 1 ml of perfusate was collected, and perfusate volume was 
replenished with fresh perfusate. The collected perfusate was centrifuged (1,100 × g for 30 min) 
to pellet erythrocytes and perfusate plasma was then assayed for TG concentration using an 
enzymatic assay as described previously (15). A plot was then made of perfusion time versus TG 
concentration for each animal; lipid accumulation rates were obtained from the slope of the line 
of best fit, determined by linear regression analysis using GraphPad Prism 5® software 
(GraphPad Software, Inc., San Diego, CA). 
VLDL Subfractionation and Particle Size Analysis  
For plasma lipoprotein fractionation, 200 μl of pooled plasma (n = 3 per genotype) was first 
adjusted to d = 1.10 g/ml with solid KBr in 4 ml of saline. Plasma was overlaid with 3 ml of d = 
1.065 g/ml NaBr, 3 ml of d = 1.02 g/ml NaBr, and 3 ml of d = 1.006 g/ml NaCl in a Beckman 
SW40 centrifuge tube. After ultracentrifugation at 40,000 rpm for 148 min at 20 °C, VLDL1 (Sf 
> 100) was collected from the top 1 ml of the gradient. Following a subsequent 
ultracentrifugation at 37,000 rpm for 18 h at 15 °C, VLDL2 (Sf 20–100) and other lipoproteins 
were collected from the top into 11 fractions (1 ml each). TG concentration in each fraction was 
determined by enzymatic assay. VLDL size from an equal volume of pooled VLDL1 and 
VLDL2 was analyzed using a Zetasizer Nano S® dynamic light scattering instrument (Malvern). 
Particle sizes are reported as median peak diameter using volume analysis. 
In Vivo Determination of VLDL TG and ApoB Secretion Rate  
After a 4-h fast, male mice (n = 3 of each genotype) were anesthetized and injected in the 
peritoneal cavity with poloxamer 407 (1,000 mg/kg; Sigma), to block lipolysis and with 
[3H]oleate (5 μCi/g body weight) and [35S]Cys/Met (7 μCi/g body weight) as tracers of TG and 
protein synthesis, respectively (16, 17). To study the effect of in vivo inhibition of PI3K on 
VLDL TG and apoB production, mice were injected with the PI3K inhibitor wortmannin (1.5 
μg/g body weight) 1 h prior to detergent injection as described previously (18). Fifty μl of blood 
were collected from anesthetized mice by retro-orbital bleeding at 0, 1, 2, and 4 h after injection. 
Plasma was harvested from the blood samples and used to quantify TG mass by enzymatic assay 
and radiolabel incorporation into newly secreted VLDL TG and apoB. Briefly, plasma was lipid-
extracted, TG was fractionated by thin layer chromatography, and radiolabel in the TG band was 
quantified by liquid scintillation counting. TG secretion rates were derived from the slope of the 
line of best fit of time versus plasma [3H]TG plots for each individual animal using GraphPad 
Prism 5. To measure secretion of newly synthesized apoB, 10 μl of the terminal plasma sample 
were immunoprecipitated with goat anti-human apoB antiserum (5 μg) in buffer containing 1% 
Triton X-100, 0.1% SDS, 0.5% sodium deoxycholate, 0.2% bovine serum albumin, protease 
inhibitors, and phosphatase inhibitor (i.e. immunoprecipitation buffer). After 18 h of incubation 
of the samples with rotation at 4 °C, 20 μl of protein G beads (50:50 slurry; Amersham 
Biosciences) were added for 2 h. Beads were collected by centrifugation at 10,000 rpm for 10 s 
and washed three times with lysis buffer. Proteins were eluted from the beads by heating (70 °C 
for 10 min) in SDS-PAGE sample buffer and fractionated by 4–8% gradient SDS-PAGE. Gels 
were then dried and visualized with a PhosphorImager. 
Plasma Lipase Activity  
To prepare post-heparin plasma, mice were first anesthetized, and then 300 units/kg heparin was 
injected via the tail vein (n = 7–8 per genotype). Blood was collected by cardiac puncture 15 min 
after heparin injection using a heparin-coated syringe. Hepatic lipase (HL) and LPL activities 
were measured in the post-heparin plasma (20 μl) using a radiolabeled triolein-Triton X-100 
mixed micellar substrate as described previously (19). HL activity was measured as the activity 
in the presence of 1 m NaCl or in the absence of apoC-II activator. LPL activity was calculated 
as total activity minus HL activity. Lipolytic activities were expressed as μmol of fatty acid 
released/h/ml of plasma. 
Postprandial Lipemia Study  
Age- and body weight-matched male mice (n = 4 of each genotype) were fasted for 4 h, 
beginning at 6:00 a.m. For basal level TG measurement, 20 μl of blood was collected from the 
tail vein, prior to oral administration of 150 μl of olive oil. Subsequent bleeds followed at 0.5, 1, 
2, 4, and 8 h post-gavage. Plasma concentrations of triglycerides were determined by an 
enzymatic assay as described above. 
Hepatic PI3K Activation  
To determine the activation of hepatic PI3K after acute insulin injection, mice were anesthetized 
with ketamine/xylazine, the portal vein was exposed, and 5 units insulin/kg body weight were 
injected. Five min later, liver was isolated and snap-frozen in liquid N2 and kept at −80 °C until 
analyses were performed. Liver homogenates were prepared in the presence of 
protease/phosphatase inhibitor mixture (Sigma) and subsequently used for Western blot analysis 
of total PI3K p85 and phospho-PI3K 85 expression. For the fast/refeeding studies, mice were 
moved to individual clean cages (with free access to water) and fasted for 15 h, re-fed for 2 h, 
and then fasted for an additional 2 h to allow clearance of chylomicrons (i.e. refed group) before 
the mice were euthanized for liver collection. The fasted group was fasted for a total of 19 h 
before liver collection. 
Primary hepatocytes from WT and HSKO mice were isolated as described previously (1) and 
used for PI3K activation and TG secretion studies. Briefly, the portal vein was cannulated, and 
the liver was perfused at a rate of 4 ml/min with a calcium- and magnesium-free buffer (10 mm 
HEPES, pH 7.4, 0.5 mm EDTA), followed by a collagenase solution (0.3 mg/ml collagenase I, 
Worthington). Hepatocytes released from the liver capsule and intact hepatocytes were isolated 
by two rounds of centrifugation at 50 × g for 5 min. Cells were plated into 35-mm dishes 
precoated with collagen (Sigma) at a density of 0.5 × 106 cells/dish in William's E medium 
containing 5% fetal bovine serum, 2 mm l-glutamine, 0.1 nm insulin (Sigma), 100 units/ml 
penicillin, and 100 μg/ml streptomycin. The PI3K activation was evaluated as mentioned above, 
and TG secretion were measured as we described previously (12). 
LDL Turnover  
LDL was isolated from 2 ml of LDLrKO plasma by sequential ultracentrifugation (Beckman 
Instruments, Palo Alto, CA) at d = 1.019–1.063 g/ml. The isolated mouse LDL preparation was 
radiolabeled with 125I using the iodine monochloride method (20). Specific activity of the 125I-
LDL tracer was 308 cpm/ng protein, trichloroacetic acid-precipitable 125I radioactivity was 97%, 
and lipid radiolabeling was negligible. The 125I-LDL tracer also eluted with authentic LDL on a 
Superose 6 FPLC column. Recipient mice (n = 4/genotype) were anesthetized with isoflurane, 
and 0.5 × 106 cpm of the radiolabeled tracer were injected via the tail vein. Blood samples (30 
μl) were drawn at 2, 10, and 30 min and 1, 3, 6, and 22 h after tracer injection by retro-orbital 
bleeding of anesthetized mice. 125I-apoB (apoB-48 plus apoB-100) was precipitated from 15 μl 
of plasma using isopropyl alcohol, with human LDL (100 μg) as a carrier (17), and 125I 
radiolabel was determined by γ-scintillation spectrometry. Turnover curves were plotted as a 
percentage of the 2-min plasma radioactivity remaining in plasma after injection of the tracers. 
Fractional catabolic rate (FCR) was calculated for individual plasma die-away curves using a 
biexponential curve-fitting program in GraphPad Prism 5. 
Adenoviral Overexpression of hABCA1  
Adenoviruses expressing full-length human ABCA1 (Ad-ABCA1) and alkaline phosphatase 
(Ad-AP) were generated was previously described (21, 22). The titration of recombinant 
adenovirus was performed using a commercial titration kit (Adeno-XTM Rapid Titer kit, 
Clonetech). Preinfection blood samples of non-fasted WT and HSKO mice fed a HF diet for 8 
weeks were collected at 9:00 a.m. via tail vein bleeding. Adenoviral vectors were diluted in 
sterile PBS and intravenously delivered to WT and HSKO mice (n = 4/group) at a dose of 3 × 
108 infectious units/mouse (21, 22). Three days after Ad-AP or Ad-ABCA1 infection, blood and 
liver samples were collected at 9:00 a.m. from the non-fasted WT and HSKO recipient mice. 
Real-time PCR Analysis  
Total RNA was isolated from liver of age-matched male mice using TRIzol (Invitrogen), and 
real-time PCR was performed as described previously (23). Primer sequences for ABCA1, 
ABCG1, SRBI, SREBP2, LXRα, LXRβ, and GAPDH expression were the same as reported 
previously (23). Sequences for ABCG5, LRP, LDLr, SREBP1c, PPARα, PPARγ, PGC1α, and 
FXRα are summarized in supplemental Table 1. GAPDH was used as an endogenous control. 
Western Blotting  
Mouse liver extract was prepared by homogenizing ∼500 mg of frozen liver with a Polytron 
homogenizer in radioimmune precipitation lysis buffer containing protease inhibitor and 
phosphatase inhibitor mixture (Sigma). Western blots were performed as previously described 
(1). Polyclonal antibodies targeting phospho-PI3K p55/p85, phospho-Akt (Ser473), and total Akt 
were purchased from Cell Signaling Technology. Antibodies against human apoB and mouse 
apoA-I were purchased from Biodesign. Antibody against endothelial lipase was purchased from 
Cayman Chemical. Polyclonal antibodies directed at LDLr and apoE were provided by Dr. 
Liqing Yu (Wake Forest University Health Sciences). 
Statistics  
Results are presented as means ± S.E. Data were statistically analyzed using Student's t test or 
one-way analysis of variance with Tukey's multiple comparisons. 
RESULTS 
Targeted Deletion of Hepatocyte ABCA1 Results in Postprandial Hypertriglyceridemia  
HSKO mice were generated by crossing ABCA1-floxed mice with albumin Cre transgenic mice 
as described previously (1). To determine the potential effect of hepatocyte ABCA1 expression 
on plasma TG concentrations, both fasted and non-fasted mice were studied. There was no 
significant difference in TG levels in fasting WT and HSKO mice (Fig. 1A); however, in the 
non-fasting state, there was a significant elevation in plasma TG concentrations with successive 
deletion of hepatic ABCA1 alleles (63 ± 4, 82 ± 4, and 152 ± 13 mg/dl for WT, heterozygous, 
and homozygous HSKO, respectively) (Fig. 1B). Plasma apoB48 levels also demonstrated a 
stepwise increase with loss of hepatic ABCA1 expression, whereas apoB100 levels displayed a 
decrease in abundance that was particularly dramatic in homozygous HSKO mice (Fig. 1C). To 
further characterize the lipoprotein response in non-fasted mice, pooled plasma was fractionated 
by FPLC. In addition to a striking reduction of HDL cholesterol as described previously (1), loss 
of hepatic ABCA1 gene function caused a dose-dependent decrease in LDL cholesterol and LDL 
TG and an increase in VLDL cholesterol and VLDL TG (Fig. 1D). Western blot analysis of 
FPLC fractions corresponding to the major lipoprotein classes (Fig. 1E) revealed that hepatic 
inactivation of ABCA1 caused a gene dose-dependent increase in apoB48 and -100 in VLDL but 
a decrease in LDL. Thus, the whole plasma Western blot results in Fig. 1C can be explained by 
the increase of plasma apoB in VLDL and the decrease in LDL that occurs in HSKO mice 
relative to WT mice. It was also notable that inactivation of ABCA1 reduced apoE in the LDL 
and HDL fractions. As expected, apoA-I in HDL was reduced in the HSKO mice (Fig. 1E). 
Collectively, these data demonstrate that hepatocyte-specific inactivation of ABCA1 induces 
postprandial hypertriglyceridemia, characterized by an increase in plasma VLDL and a decrease 
in plasma LDL, recapitulating the TD lipid phenotype (10, 24). 
Deletion of Hepatocyte ABCA1 Increases Hepatic TG Secretion and Reduces Post-heparin Plasma Lipolytic 
Activity  
To determine whether hepatic production of TG contributes to the elevated levels of plasma TG 
in HSKO mice, we performed two studies. First, we measured hepatic TG mass secretion using 
isolated recirculating liver perfusion. The TG accumulation rate in liver perfusate of HSKO mice 
was twice that of WT mice (3.40 ± 0.20 versus 1.87 ± 0.07 μg/g liver/min; p < 0.001), suggesting 
hepatic TG mass secretion is increased in the absence of ABCA1 (Fig. 2A). In the second 
experiment, TG and apoB production were measured in vivo in the presence of the detergent 
poloxamer 407, to block TG lipolysis. Radiolabeled precursors ([3H]oleic acid and [35S]Met/Cys) 
were injected with the detergent, and the appearance of newly synthesized and secreted TG and 
apoB was monitored. In agreement with the liver perfusion data, the rate of TG secretion was 
2.6-fold higher in HSKO mice relative to WT mice (Fig. 2B, top). Analysis of total radiolabeled 
apoB in the terminal plasma sample showed a 1.6-fold increase (1.4-fold in apoB100 and 1.73-
fold in apoB48) in HSKO versus WT mice (Fig. 2B, bottom). Collectively, these data suggest 
that deficiency of hepatic ABCA1 expression increases hepatic TG secretion. 
To determine whether reduced plasma lipolytic activity also contributed to the elevation of 
plasma TG in HSKO mice, HL and LPL activity were measured in post-heparin plasma using 
[3H]triolein micelles as substrates. HSKO mice displayed a 50% reduction in total lipase activity 
relative to WT mice (18.86 ± 1.10 versus 10.10 ± 0.40 μmol of fatty acid released/h/ml of 
plasma), which was due to a ∼30% reduction in HL activity (11.10 ± 0.64 versus 7.69 ± 0.28) 
and a ∼70% reduction in LPL activity (7.76 ± 0.58 versus 2.4 ± 0.25) (Fig. 2C). In agreement 
with the reduced lipase activity, HSKO mice displayed delayed clearance of an oral fat load 
compared with WT mice (Fig. 2D). TPC during the oral fat load was constant for heterozygote 
and WT mice but showed a slight increase in HSKO mice, presumably due to the delayed 
clearance of chylomicron remnants and the low basal cholesterol concentrations in HSKO mouse 
plasma. Taken together, these data suggest that, in addition to effects on TG secretion, hepatic 
ABCA1 deficiency also affects the clearance of apoB lipoproteins. 
To address whether hepatic deletion of ABCA1 altered hepatic lipid homeostasis, liver lipid 
content was analyzed. Total cholesterol (2.39 ± 0.15 versus 2.84 ± 0.3 μg/mg liver, p = 0.20), 
free cholesterol (1.62 ± 0.15 versus 1.66 ± 0.15 μg/mg liver, p = 0.87), and TG content (13.41 ± 
2.02 versus 15.17 ± 3.45 μg/mg liver, p = 0.65) were similar for WT versus HSKO mice, 
respectively (Fig. 3A). Expression of hepatic lipid metabolism-related genes (Fig. 3B), fatty acid 
composition of liver lipids (Fig. 3C), and total free fatty acid content (Fig. 3D) were similar 
between the two genotypes of mice. Together, these data indicate that, despite alterations in TG 
secretion and lipolytic activity associated with inactivation of hepatic ABCA1, no major changes 
occurred in hepatic lipid content. 
Loss of Hepatocyte ABCA1 Expression Increases Nascent VLDL Size and Attenuates PI3K Signaling  
Overproduction of VLDL TG occurs in diabetes and metabolic syndrome and is associated with 
an increase in VLDL particle size (25, 26). To determine whether increased hepatic TG secretion 
in HSKO mice is associated with secretion of larger, more buoyant VLDL, pooled plasma (n = 3) 
was fractionated by density gradient ultracentrifugation into VLDL1 (Sf = 100–400) and VLDL2 
(Sf = 20–100). As anticipated, there was a significant increase of VLDL1-TG in HSKO mice 
relative to WT mice, suggesting secretion of larger VLDL particles (Fig. 4A). In support of this 
result, VLDL size (measured by dynamic laser light scattering) was larger in HSKO (79.1 ± 0.4 
nm) compared with WT mice (42.5 ± 3.1 nm) (Fig. 4B). Examination of VLDL (VLDL1 and -2) 
apolipoprotein content by Western blot analysis using an equivalent amount of VLDL protein (4 
μg) revealed that VLDL from HSKO mice had more apoB48, apoB100, and apoA-I and less 
apoE (apoE/apoB ratio = 0.49 relative to WT) compared with WT mouse VLDL (Fig. 4C). 
Previously, we showed that silencing of ABCA1 in rat hepatoma cells was associated with 
elevated TG secretion, increased VLDL particle size, and reduced PI3K activation (12). To 
examine whether PI3K activation was diminished in livers of HSKO mice, we stimulated the 
PI3K pathway by acute insulin administration or by subjecting mice to a fasting/refeeding 
protocol. Portal vein injection of insulin (5 units/kg) induced robust phosphorylation of PI3K p85 
in WT liver, whereas there was a 28% decrease in HSKO liver (Fig. 5A; WT versus HSKO was 1 
versus 0.72 ± 0.008; n = 3 mice/treatment, p = 0.031). In the fasting/re-feeding experiments, 
PI3K phosphorylation was reduced 31% in HSKO compared with WT liver (Fig. 5B; 1 versus 
0.72 ± 0.004; n = 3 mice per treatment, p = 0.01), and Akt phosphorylation was 63% lower (1 
versus 0.36 ± 0.059; n = 3 mice/treatment, p = 0.038). Moreover, in vivo pharmacological 
inhibition of PI3K by wortmannin, prior to detergent blockage of lipolysis, had little effect on 
plasma TG and secretion of newly synthesized apoB in HSKO mice (Fig. 5C, HSKO ± Wort). 
On the other hand, in vivo inhibition of PI3K activation with wortmannin in WT mice resulted in 
increased plasma TG as well as apoB secretion (+/+; compare ± Wort), to levels similar to those 
observed in HSKO mice (Fig. 5C). Effects of PI3K activation on hepatic TG secretion was also 
investigated in primary hepatocytes. Synthesis and secretion of TG from [3H]oleate was almost 
3-fold higher in HSKO mice (Fig. 5D). Consistent with in vivo results, phosphorylation of PI3K 
p85 was diminished in primary hepatocytes from HSKO mice as compared with WT mice (Fig. 
5D). However, hepatic microsomal transfer protein (MTP) mRNA and protein levels were 
similar (Fig. 5E), suggesting that up-regulation of MTP is not the basis for increased TG 
secretion caused by hepatic ABCA1 deficiency. These data provide mechanistic evidence that 
targeted inactivation of hepatic ABCA1 attenuates activation of PI3K, which in turn, contributes 
to increased secretion of larger TG-enriched VLDL. 
Selective Hepatocyte ABCA1 Deletion Increases Plasma Clearance of LDL  
To determine whether loss of hepatic ABCA1 expression contributes to reduced plasma LDL 
concentrations by increasing LDL clearance from plasma, we performed turnover studies using 
LDL isolated from LDLrKO mice. Isolated LDL was radioiodinated with 125I and intravenously 
injected into WT and HSKO recipient mice, after which plasma clearance of the 125I-LDL tracer 
was measured. The LDL tracer was removed from plasma more rapidly in HSKO recipient mice 
compared with WT mice (Fig. 6A). The FCR (pools/day) of 125I-LDL apoB was significantly (p 
< 0.001) higher in HSKO mice than WT mice (5.26 ± 0.28 versus 2.95 ± 0.15) (Fig. 6A). 
Surprisingly, hepatic LDLr mRNA (Fig. 6B) and protein (Fig. 6C) abundance were markedly 
increased in the absence of hepatic ABCA1, suggesting that hepatic LDLr-mediated clearance 
contributed to the higher LDL FCR observed in HSKO mice. 
To further explore this hypothesis, we crossed HSKO mice with LDLrKO mice. In the LDLrKO 
background, there was still a significant elevation in plasma TG concentrations associated with 
successive deletion of hepatic ABCA1 alleles (60.7 ± 2.0, 69 ± 3.9, 93.8 ± 7.0 mg/dl for WT, 
heterozygous, homozygous HSKO in LDLrKO background; Fig. 6D, top), similar to the plasma 
TG response trend of mice with functional LDL receptors (Fig. 1B). Although total plasma 
cholesterol was significantly lower in HSKO mice in the LDLrKO background (Fig. 6D, 
bottom), this was due to exclusively to a marked decrease in HDL cholesterol (46 versus 8 mg/dl 
in LDLrKO versus LDLrKO, HSKO mice; Fig. 6F). However, in contrast to LDL-replete mice 
(Fig. 1D), LDL cholesterol concentrations were similar (106 versus 103 mg/dl in LDLrKO 
versus LDLrKO, HSKO mice) (Fig. 6F), suggesting that hepatic LDLr-mediated clearance is the 
major cause for reduced LDL concentrations in HSKO mice. There was also a decrease in 
scavenger receptor B-I and endothelial lipase expression in HSKO liver (supplemental Fig. 1). In 
summary, the significantly lower plasma LDL concentrations in HSKO mice appear to be due to 
more rapid plasma clearance of LDL particles, secondary to increased hepatic LDLr expression. 
Adenoviral Repletion of ABCA1 Normalizes Plasma TG Concentrations in High Fat-fed HSKO Mice  
To determine whether repletion of hepatic ABCA1 would reverse the plasma lipid phenotype of 
HSKO mice, we injected intravenously Ad-ABCA1 or Ad-AP (control) into WT and HSKO 
mice fed an HF diet for 8 weeks. The HF diet was employed to more closely mimic the human 
dietary situation and to increase plasma and liver lipid concentrations. Three days after injection, 
Ad-ABCA1 had restored ∼60% of WT hepatic ABCA1 expression in HSKO mice, whereas it 
induced a 2-fold increase in hepatic ABCA1 levels in WT mice (Fig. 7A; the anti-ABCA1 
antibody was raised using a peptide whose sequence is identical between mouse and human 
ABCA1). Consistent with data generated using chow-fed mice (Fig. 6C), hepatic LDLr protein 
expression was also higher in HF-fed HSKO mice compared with WT mice; however, in neither 
background did short term overexpression strongly impact hepatic LDLr expression. Moreover, 
similar to results in chow-fed mice (Fig. 5, A and B), PI3K phosphorylation was reduced in HF-
fed HSKO mice; however, partial repletion of hepatic ABCA1 in HSKO by adenoviral delivery 
of human ABCA1 restored PI3K phosphorylation to a level comparable with levels in Ad-
ABCA1-treated WT liver (Fig. 7A). TPC was significantly increased in WT mice injected with 
Ad-ABCA1 compared with Ad-AP (Fig. 7B; 251 ± 23 versus 154 ± 3 mg/dl; n = 4) due to 
increases in LDL and HDL cholesterol (Fig. 7C). In HSKO mice, Ad-ABCA1 expression 
actually decreased TPC concentration (Fig. 7B) by decreasing VLDL cholesterol concentration 
to a greater extent than it increased HDL cholesterol (Fig. 7D). Plasma TG concentration was 
unchanged in WT mice injected with Ad-ABCA1 versus Ad-AP (Fig. 7B) due to an increase in 
VLDL TG and a reciprocal decrease in LDL TG (Fig. 7E). In HSKO mice, Ad-ABCA1 injection 
resulted in a normalization of plasma TG concentration to WT levels (Fig. 7B) and a striking 
decrease in VLDL TG (Fig. 7F). Because plasma lipase activity was unchanged over the 
relatively short time course of the adenovirus experiment (data not shown), it is likely that the 
decreased plasma TG levels in HSKO mice treated with Ad- ABCA1 was due to decreased 
hepatic TG secretion, not increased TG hydrolysis. Unlike the situation in chow-fed mice in 
which hepatic liver lipid content was similar between WT and HSKO mice (Fig. 3A), HF-fed 
HSKO mice displayed a paradoxical decrease in hepatic TG and TC content relative to WT mice 
(Fig. 7G), and acute repletion of hepatic ABCA1 did not affect hepatic lipid content in either 
genotype of mice. These results demonstrate that acute, partial (60%) repletion of hepatic 
ABCA1 expression in HSKO mice can normalize plasma TG concentrations within 3 days, 
although HDL cholesterol concentrations were not fully recovered to WT levels. 
DISCUSSION 
It is well established that ABCA1 influences HDL metabolism in humans, mice, and chickens 
(27); however, its role in metabolism of apoB-containing lipoproteins remains elusive. In the 
present study, we demonstrated that targeted inactivation of ABCA1 in hepatocytes recapitulates 
the lipid phenotype of TD subjects, including reduced HDL and LDL cholesterol, and elevated 
TG concentrations. We established that part of the lipid phenotype associated with hepatic 
ABCA1 deficiency results from an increased secretion of TG-enriched hepatic VLDL via a 
PI3K-dependent pathway. We also documented decreased post-heparin lipolytic activity and 
increased hepatic LDLr expression, resulting in a net increase in clearance of LDL from the 
circulation. Furthermore, elevated plasma VLDL TG was rescued by adenoviral expression of 
human ABCA1, demonstrating the existence of a coupled regulatory pathway between HDL and 
apoB Lps through hepatic ABCA1. The combined results suggest that, in addition to its well 
recognized role in HDL biogenesis, hepatic ABCA1 plays a significant and complex role in 
apoB LP metabolism. 
Previously, we reported that silencing of ABCA1 in rat hepatoma cells decreased formation of 
large (>10-nm diameter) nascent HDL particles, increased secretion of large, buoyant TG-
enriched VLDL, and attenuated PI3K activation (12). We further demonstrated that the addition 
of nascent HDL particles, the product of ABCA1-mediated lipidation of apoA-I, to ABCA1-
silenced hepatoma cells reversed the blockage of PI3K activation and restored the basal rate of 
TG secretion. The present study demonstrates the physiological relevance of our previous in 
vitro observations using rat hepatoma cells and suggests a new mechanism for the elevated 
plasma TG concentrations associated with TD. We show that selective hepatic ABCA1 
deficiency in mice increases hepatic VLDL TG secretion ex vivo, using isolated liver perfusion 
(Fig. 2A) and cultured primary hepatocytes (Fig. 5D), and in vivo, using detergent to block 
VLDL catabolism (Fig. 2B). Furthermore, as assessed by both differential ultracentrifugation and 
dynamic laser light scatter data, hepatic ABCA1 deficiency resulted in the formation of larger, 
TG-enriched VLDL particles (Fig. 4, A and B), similar to our previous findings with rat 
hepatoma cells (12). Finally, acute, partial repletion of hepatic ABCA1 expression with 
adenovirus resulted in normalization of plasma VLDL TG concentration (Fig. 7, B and F). These 
results collectively suggest a mechanistic link between nascent HDL formed by ABCA1 and 
hepatic VLDL TG secretion. 
The mechanism responsible for ABCA1-mediated regulation of VLDL assembly and secretion 
appears to involve a PI3K-dependent pathway based on multiple lines of evidence. First, HSKO 
mice demonstrated attenuated phosphorylation of hepatic PI3K p85 and its downstream target, 
Akt, in response to both acute injection of insulin- and glucose-stimulated endogenous insulin 
release (i.e. fasting-refeeding; Fig. 5, A and B). Second, diminished PI3K activation was 
observed in cultured primary hepatocytes from HSKO mice in conjunction with increased TG 
secretion (Fig. 5D). Third, plasma TG concentrations of WT mice were elevated to levels similar 
to those of HSKO mice after acute in vivo inhibition of PI3K with wortmannin (Fig. 5C). Finally, 
partial adenoviral repletion of hepatic ABCA1 rescued PI3K activation and normalized plasma 
TG concentrations (Fig. 7, A and F). These results, along with our previous in vitro data (12), 
firmly establish a mechanistic link through which hepatic ABCA1 expression regulates hepatic 
PI3K activity, hepatic TG secretion, and plasma TG concentration. 
The relationship between VLDL particle assembly and PI3K has been noted previously and, in 
part, underlies the ability of insulin to acutely regulate hepatic VLDL TG output (28,–30). The 
interface between PI3K-dependent signaling and apoB assembly and secretion is not known in 
detail, although in some studies, insulin-mediated signaling, via PI3K and Akt, regulates MTP 
expression and, hence, VLDL particle number and size (18, 29, 31, 32). Although MTP is the 
target for some forms of PI3K-mediated regulation of VLDL assembly (32), MTP expression 
was unaffected by ABCA1 deficiency in this study (Fig. 4E) or by silencing of ABCA1 in rat 
hepatoma cells in our previous study (12), suggesting that other mechanisms are operational. 
VLDL particle assembly occurs in two steps: the co-translational lipidation of apoB by MTP to 
form a small, dense apoB-containing pre-VLDL, followed by a pre-VLDL particle fusion with 
TG lipid droplets in the secretory pathway to form mature VLDL particles (33, 34). Several 
studies have indicated that the insulin/PI3K effects on VLDL production occur during the 
second, pre-VLDL enlargement step of particle assembly (28, 30). The current studies 
demonstrate that VLDL from HSKO mice is more buoyant and of larger diameter than that of 
WT mice, which is also consistent with ABCA1/PI3K exerting effects during the second step of 
VLDL assembly. Because PI3K is present in the endoplasmic reticulum and Golgi, is involved in 
intracellular vesicular trafficking, and is increased with insulin stimulation (29, 35, 36), we 
hypothesize that the lack of ABCA1 in hepatocytes and the resultant attenuation of PI3K 
activation results in slower VLDL transit through the secretory pathway, allowing additional 
time for second step VLDL particle expansion. This hypothesis is supported by the observations 
of defective lipid and vesicular trafficking from the Golgi to the plasma membrane in fibroblasts 
from TD subjects (37,–40). 
Reduced LPL activity has also been suggested to explain the elevated TG levels in TD subjects. 
For example, Wang et al. (10) showed that VLDL from TD subjects was enriched with apoA-II 
and apoC-III, compared with VLDL from normolipidemic subjects, resulting in a reduced lipase 
accessibility. Consistent with this notion, Kyreos et al. (41) recently showed that adenoviral 
overexpression of human apoC-III in apoE KO and ABCA1 KO mice induces 
hypertriglyceridemia due to low LPL reactivity of apoC-III-enriched VLDL. In addition to 
possible effects on VLDL substrate, our mouse model also showed that both HL and LPL were 
markedly reduced upon deletion of hepatic ABCA1 (Fig. 2C). Therefore, it is likely that the 
decrease in HL and LPL in HSKO mice contributed, in large part, to the increase in plasma TG 
and apoB48 levels observed in the postprandial state (Figs. 1, B and C, and and22D). These 
findings may explain why elevated plasma TG levels in TD patients are more evident 
postprandially (9). 
Despite elevated plasma TG concentrations, TD subjects have LDL concentrations that are 
reduced by ∼40–50% (8). Schaefer et al. (42) demonstrated that this was due to a 2-fold increase 
in FCR of LDL. Supporting this finding, Zha et al. (43) reported enhanced uptake of LDL by 
fibroblasts from TD subjects that appeared related to increased endocytosis. Similar to TD 
subjects, HSKO mice demonstrated a 2-fold increased removal rate of LDL tracer from plasma 
compared with WT mice (Fig. 6A). The increased catabolism of LDL probably resulted from the 
2.5-fold increase in expression (mRNA and protein) of hepatic LDLr (Fig. 6, B and C). The 
increase in hepatic LDLr expression in HSKO mice appears unrelated to hepatic sterol content, 
because chow-fed WT and HSKO mice had similar hepatic lipid content and expression of 
cholesterol-sensitive genes (supplemental Fig. 1A). Additional evidence to support our 
conclusion that increased hepatic LDLr expression is responsible for the decreased plasma LDL 
concentrations in HSKO mice comes from our studies in which HSKO mice were crossed into 
the LDLrKO background. In the absence of whole-body LDLr expression, we observed similar 
plasma LDL concentrations in LDLrKO and HSKO-LDLrKO mice (Fig. 6F), although plasma 
TG concentrations were still significantly higher in HSKO-LDLrKO mice relative to LDLrKO 
mice. These results suggest that two separate mechanisms, increased hepatic LDLr expression 
and increased hepatic TG secretion, are responsible for the reduced plasma LDL and increased 
plasma TG concentrations, observed under conditions of hepatic ABCA1 expression deficiency. 
Transgenic LDLrKO mice with 2.3-fold overexpression of ABCA1 protein in the liver displayed 
significantly increased plasma VLDL, LDL, and HDL cholesterol concentrations, increased 
apoA-I and apoB levels, delayed clearance of VLDL and LDL tracers, and an increase in 
atherosclerosis (44). These data led to the hypothesis that liver ABCA1 may play a 
proatherogenic role in vivo, resulting from its dramatic effects on the metabolism of apoB-
containing lipoproteins. These mice also displayed increased plasma TG concentrations, perhaps 
due to a small but significantly delayed clearance of plasma VLDL particles caused by their 
cholesterol enrichment. However, a more modest overexpression of ABCA1 protein (∼25%) 
using the endogenous ABCA1 promoter in LDLrKO mice resulted in no significant increase in 
apoB-containing lipoprotein concentration and a significant reduction in atherosclerosis, 
probably due to an increase in macrophage ABCA1 protein expression (45). The reasons for the 
apparently discrepant impact of ABCA1 overexpression on LDL concentrations and 
atherosclerosis in LDLrKO mice are 2-fold. First, the regulatory elements controlling the sites 
and regulation of ABCA1 expression were different in the two studies. Second, the extent of 
ABCA1 overexpression was ∼10-fold higher when the apoE promoter was used (∼2.5-fold over 
expression) versus the endogenous ABCA1 promoter (0.25-fold increase). Indeed, when a 2.6-
fold overexpression of ABCA1 was achieved in the liver using a cytomegalovirus promoter in 
adenovirus, significant increases in the concentration of plasma proatherogenic apoB-containing 
lipoproteins as well as HDL cholesterol were observed (22). Taken together, these studies 
complement our data and demonstrate that when hepatic ABCA1 is overexpressed to a sufficient 
extent, LDL concentrations are elevated, whereas liver-specific deletion of ABCA1 results in 
reduced plasma LDL concentrations. 
In summary, our data support an important and emerging role for hepatic ABCA1 expression in 
the production and catabolism of apoB lipoproteins and suggest new mechanisms to account for 
the increased plasma TG and decreased LDL concentrations observed in TD subjects. 
Furthermore, the decreased LDL levels may explain why some TD subjects have only minimally 
increased risk of coronary heart disease despite having extremely low plasma HDL levels (4). 
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Figures and Tables 
FIGURE 1. 
 
Targeted deletion of hepatocyte ABCA1 induces hypertriglyceridemia. Plasma was collected 
from fasted (A) and non-fasted (B–E) wild type (+/+), heterozygous (Hetero), and homozygous 
HSKO mice. A, fasted (6 h) plasma TG concentrations, mean ± S.E. ns, not significant. B, non-
fasted plasma TG concentrations, mean ± S.E. *, p < 0.05; **, p < 0.01; ***, p < 0.001. C, 
Western blot analysis of hepatic ABCA1 expression and plasma levels of apoB100 and apoB48. 
Twenty μl of plasma were immunoprecipitated with anti-human apoB antibody, and the 
immunoprecipitates were fractionated by SDS-PAGE and Western blotted using the same anti-
human apoB antibody. D, FPLC profiles of cholesterol (top) and triglyceride (bottom) in pooled 
plasma (450 μl; n = 6/genotype). Insets show the VLDL cholesterol (top) and LDL TG (bottom) 




Selective deletion of hepatocyte ABCA1 increases hepatic TG secretion and reduces post-
heparin lipase activity. A, TG mass accumulation per g of liver during isolated recirculating 
liver perfusion of WT (+/+) (n = 6) and HSKO (n = 5) mice. Data points denote mean TG ± S.E. 
of mice of the indicated genotype at each time point; the line of best fit, determined by linear 
regression analysis, is shown for both genotypes. Accumulation rates (μg/g liver/min) of TG 
were derived by linear regression analysis of the slope of the plot for each mouse. The mean ± 
S.E. accumulation rate was 1.87 ± 0.07 and 3.40 ± 0.20 μg/min/g liver for WT and HSKO mice, 
respectively. B, appearance of newly synthesized plasma TG and apoB after detergent block (n = 
3 for each genotype). Data points denote the mean ± S.E. of radiolabeled TG in 100 μl of plasma; 
the line of best fit, determined by linear regression analysis, is shown for both genotypes. 
Accumulation rates were derived by linear regression analysis of the slope of the plot for each 
mouse; mean ± S.E. accumulation rates ([3H]TG/100 μl of plasma/h) of TG were 51,550 ± 6,205 
and 136,500 ± 12,480 for WT and HSKO mice, respectively. Accumulation of newly 
synthesized and secreted plasma apoB in the terminal plasma sample was determined after 
immunoprecipitation with anti-apoB antiserum, SDS-PAGE separation of proteins, and 
PhosphorImager analysis. Relative PhosphorImager intensity of total apoB (apoB100 + B48), 
normalized to a WT mouse sample, is shown below the gel. C, plasma isolated 15 min after 
intravenous heparin injection (300 units/kg) was used to measure the HL and LPL activity in WT 
(+/+, n = 8) and HSKO (n = 7) mice. D, plasma TG and TC concentration after oral gavage of 
olive oil (150 μl) in WT (+/+) and HSKO mice (n = 4/group). Data expressed in mean ± S.E. *, p 
< 0.05; ***, p < 0.001 by Student's t test. 
FIGURE 3. 
 
Targeted deletion of hepatocyte ABCA1 does not alter liver lipid content, gene expression, 
or lipid fatty acid composition. A, liver lipid content (TG, TC, free cholesterol (FC), and 
cholesteryl ester (CE)) in chow-fed wild type (+/+, n = 11) and HSKO (n = 9) mice was analyzed 
by enzymatic assays, and results were normalized to liver wet weight. B, mRNA expression of 
genes related to lipid metabolism were analyzed by quantitative real-time PCR and normalized to 
GAPDH expression. Mean ± S.E., n = 6/genotype. C, fatty acid (FA) composition of hepatic 
cholesteryl ester, TG, and phospholipid (PL) from wild type (+/+, n = 3) and HSKO (+/+, n = 3) 
mice was determined by gas-liquid chromatography. Percentage distribution of polyunsaturated 
fatty acids (PUFA; n-3 and n-6), monounsaturated fatty acids (MUFA), and saturated fatty acids 
(SFA) is shown in each column. D, hepatic free fatty acid (FFA) content was determined in liver 
from wild type and HSKO mice (n = 5/group) by enzymatic assay. Data are expressed as mean ± 
S.E. ns, not significant at p = 0.05 by Student's t test. 
FIGURE 4. 
 
Targeted deletion of hepatocyte ABCA1 increases plasma VLDL size. A, fractionation of 
VLDL1 (Sf = 100–400) and VLDL2 (Sf = 20–100) in pooled plasma (n = 3/genotype, 200 μl 
total) by density gradient ultracentrifugation. VLDL1 and -2 were then assayed for TG 
concentration. B, VLDL size determination of pooled VLDL1 and VLDL2 fractions (equal 
volumes) by dynamic laser light scattering. C, VLDL fractions from A were concentrated, and 4 
μg of VLDL protein was separated by 4–16% SDS-PAGE and transferred to polyvinylidene 




Targeted deletion of hepatocyte ABCA1 induces defective PI3K signaling. A, Western blot 
analysis of liver ABCA1, PI3K p85, and phospho-PI3K p85 expression 5 min after insulin (5 
units/kg) injection into the portal vein. B, Western blot analysis of liver phospho-PI3K p85 (p-
PI3Kp85), phospho-Akt (p-Akt), and total Akt (t-Akt) expression after fasting or 
fasting/refeeding of mice. C, PI3K inhibitor, wortmannin (1.5 μg/g body weight in DMSO), or 
DMSO alone was injected into the peritoneal cavity of mice 1 h prior to injection of detergent 
(1000 mg of poloxamer 407/kg of body weight) to block lipolysis and 7 μCi of [35S]Cys/Met/g of 
body weight as described under “Experimental Procedures.” Plasma TG concentration (mean ± 
S.E., n = 3) and apoB phosphor image (bottom) were analyzed 2 h after detergent block. Relative 
PhosphorImager intensity of apoB is shown below each lane. Values were normalized to the 
apoB100 band in the DMSO-treated WT mouse. D, triglyceride secretion ([3H]TG) and PI3K 
phosphorylation from isolated primary hepatocytes. E, quantification of MTP expression in 
livers of WT and HSKO mice by real-time PCR (mRNA pool from 3 mice/genotype; top) and 
Western blot analysis (n = 3 of each genotype; bottom). Data were normalized to GAPDH 





Hepatocyte-specific deletion of ABCA1 induces rapid LDL clearance from plasma. LDL 
from LDLrKO mice was isolated and radioiodinated with 125I. A, 125I-LDL tracer was injected 
into WT and HSKO recipient mice, and periodic blood samples were taken to quantify the 
amount of tracer remaining in plasma (results normalized to the 2 min time point). Mean ± S.E., 
n = 4. FCR values (mean ± S.E.) were calculated from individual plasma die-away curves using 
a biexponential curve-fitting program. ***, p < 0.001 by Student's t test. B, real-time PCR 
quantification of hepatic ABCA1 and LDLr mRNA levels. Data were normalized to GAPDH 
expression (mean ± S.E.; n = 6). C, liver protein (50 μg) from WT and HSKO mice was 
fractionated by SDS-PAGE and analyzed for expression of ABCA1, LDLr, and GAPDH by 
Western blot. Relative quantification of the blot is shown on the right. Data are expressed as 
mean ± S.E. D, effects of hepatic ABCA1 deficiency on non-fasting plasma TG (top) and TC 
(bottom) in the LDLrKO background. Shown are wild type (LDLrKO, +/+), heterozygous 
(LDLrKO, Hetero), and homozygous HSKO (LDLrKO, HSKO) mice (n = 4/group), mean ± S.E. 
F, FPLC-cholesterol profiles of pooled plasma of wild type (LDLrKO, +/+) and HSKO 
(LDLrKO, HSKO) mice in the LDLrKO background (n = 4/group). Inset, expanded VLDL 





Adenoviral overexpression of ABCA1 normalizes plasma TG concentrations in HSKO 
mice. Mice were fed an HF diet for 8 weeks before intravenous injection of either Ad-AP or Ad-
ABCA1. Mice were sacrificed 3 days later to collect liver and plasma samples. A, Western blot 
analysis of hepatic ABCA1, LDLr, phosphorylated PI3K (p-PI3K), and total PI3K (t-PI3K) 
expression in wild type (WT; +/+) and HSKO mice. ABCA1 and LDLr expression level were 
quantified (normalized to GAPDH). Expression relative to control mice is denoted below each 
band. B, plasma concentrations of TG and TC in WT and HSKO mice (n = 4/group) after 
adenovirus injection. Data are expressed as mean ± S.E. *, p < 0.05; ***, p < 0.001 by Student's t 
test. C, FPLC-cholesterol profile from pooled plasma of WT mice (n = 4) after adenoviral 
administration. D, FPCL-cholesterol profile from pooled plasma of HSKO mice (n = 4) after 
adenovirus administration. E, FPLC-TG profile from pooled plasma of WT mice (n = 4) after 
adenovirus administration. F, FPLC-TG profile from pooled plasma of HSKO mice (n = 4) after 
adenovirus administration. G, hepatic content of TG, TC, FC, and cholesteryl ester (CE) in WT 
and HSKO mice (n = 4/group). Data are expressed as mean ± S.E. *, p < 0.05 by one-way 
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Table 1. Gene-specific primers for qPCR  
Target mRNA Forward Primer Reverse Primer 
ABCG5 TGG CCC TGC TCA GCA TCT ATT TTT AAA GGA ATG GGC ATC TCT T 
LRP TGGGTCTCCCGAAATCTGTT CCACCGCATTCTTGAAGGA 
LDLr AGGCTGTGGGCTCCATAGG TGCGGTCCAGGGTCATCT 
SREBP1c GGCCGAGATGTGCGAACT TTGTTGATGAGCTGGAGCATGT 
PPARα ACAAGGCCTCAGGGTACCA GCCGAAAGAAGCCCTTACAG 
PPARγ CACAATGCCATCAGGTTTGG GCTGGTCGATATCACTGGAGATC 
PGC1α AACCACACCCACAGGATCAGA TCTTCGCTTTATTGCTCCATGA 
FXRα TGGGCTCCGAATCCTCTTAGA TGGTCCTCAAATAAGATCCTTGG 
MTP CCTACCAGGCCCAACAAGAC CGCTCAATTTTGCATGTATCC 
 
 
Supplement Fig. 1. A. Real time PCR quantification of hepatic mRNA levels of ABCG5, ABCG1, LRP 
and SRB-1. Data were normalized to GAPDH expression (mean ± SEM; n=3 per genotype).  B. Western 
blot analysis of hepatic SR-B1 and EL expression in WT and HSKO mice (n=3). 
	



	




